PCWG2(前列腺癌临床研究工作组)指南.pdfVIP

NIH Public Access Author Manuscript J Clin Oncol . Author manuscript; available in PMC 2014 May 05. N Published in final edited form as: I H J Clin Oncol . 2008 March 1; 26(7): 1148–1159. doi:10.1200/JCO.2007.12.4487. - P A A u Design and End Points of Clinical Trials for Patients With t h o r Progressive Prostate Cancer and Castrate Levels of M a Testosterone: Recommendations of the Prostate Cancer Clinical n u s Trials Working Group c r i p t Howard I. Scher, Susan Halabi, Ian Tannock, Michael Morris, Cora N. Sternberg, Michael A. Carducci, Mario A. Eisenberger, Celestia Higano, Glenn J. Bubley, Robert Dreicer, Daniel Petrylak, Philip Kantoff, Ethan Basch, William Kevin Kelly, William D. Figg, Eric J. Small, Tomasz M. Beer, George Wilding, Alison Martin, and Maha Hussain Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer N Center, New York, NY; Duke University Medical Center, Durham, NC; Princess Margaret I H Hospital, Toronto, Ontario, Canada; Sam Camillo Forlanini Hospital, Rome, Italy; Beth Israel - P Deaconess Medical Center; Dana-Farber Cancer Center, Boston, MA; Sidney Kimmel A Comprehensive Cancer Center at Johns Hopkins, Baltimore; National Cancer Institute, Bethesda, A u t h o r M © 2008 by American Society of Clinical Oncology a Corresponding author: Howard I. Scher, MD, Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for n u Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY